Abstract Number: 741 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Recurrent Gout Attacks During Hospitalization
Background/Purpose: While anecdotal evidence suggests that risk of recurrent gout attack increases during hospitalization and gout is one of the most common reasons for in-patient…Abstract Number: 101 • 2012 ACR/ARHP Annual Meeting
Kidney Function and the Risk of Incident Gout in A Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Background/Purpose: The 1-year cumulative incidence of gout in patients with new onset end stage renal disease is 5% and rises to 15% by 5 years,…Abstract Number: 1907 • 2012 ACR/ARHP Annual Meeting
Pharmacological Management of Gout in Italy in the Years 2005-2009: A Nationwide, Population-Based Study
Background/Purpose: Despite the increasing interest on gout, only few nationwide drug utilization studies have been conducted on this topic. The aim of this study…Abstract Number: 742 • 2012 ACR/ARHP Annual Meeting
Utility of HLA-B5801 Genotyping and Renal Dosing of the Starting Dose of Allopurinol in Preventing Allopurinol Hypersensitivity Syndrome: A Cost-Effectiveness Analysis
Background/Purpose: Allopurinol is the leading choice of urate-lowering therapy (~ 95%) for gout which affects 8.3 million US adults. However, allopurinol is associated with a…Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…Abstract Number: 168 • 2012 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects…Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…
- « Previous Page
- 1
- …
- 43
- 44
- 45